Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.

Also called NCT02044653

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 257 participants (enrolled count) (from the registry)
Sponsor
Genexine, Inc. (from the registry)
Registry
  • NCT NCT02044653
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02044653. Randomized; single masking; primary purpose treatment. Start 2014-04-15 (actual); primary completion 2017-04-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
Condition
Anemia
Intervention (Drug)
GX-E2
Intervention (Drug)
GX-E2
Intervention (Drug)
GX-E2
Intervention (Drug)
NESP
Intervention (Drug)
MIRCERA
Lead sponsor
Genexine, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02044653
Content hash
8a51b212bcb8f03595a9d565cd5c3d737de4691609025ffd52402ce7707b0580